Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company, is set to present exciting preclinical data regarding its RaniPill® capsule technology at ObesityWeek® 2025, which will take place in Atlanta, Georgia, from November 4-7, 2025. The presentation aims to showcase the efficacy of oral semaglutide (RT-116) in a study involving dogs, highlighting that its bioavailability matches that of subcutaneous injections while also delivering comparable weight loss results.

Scheduled for November 6, 2025, during a dedicated poster session, the research will be presented by Dr. Kyle Horlen, Vice President of Nonclinical Development at Rani Therapeutics. The poster, numbered 647, will be located in Exhibit Hall A1 at the Georgia World Congress Center. This session is expected to draw significant attention from researchers, clinicians, and investors interested in breakthroughs in obesity treatment and drug delivery innovations.

Rani Therapeutics specializes in developing novel oral delivery systems aimed at simplifying the administration of biologics and drugs, which traditionally require injections. The RaniPill® capsule is a proprietary technology designed to enable patients to take medications orally, enhancing convenience and compliance. Previous studies have demonstrated the safety, tolerability, and bioavailability of the RaniPill® capsule, marking a significant advancement in drug delivery systems.

As Rani Therapeutics prepares for its presentation, it aims to position itself as a key player in the biopharmaceutical industry, potentially revolutionizing treatment options for obesity and other conditions requiring injectable therapies. With increasing interest in non-invasive drug delivery methods, Rani's developments could reshape the landscape of how therapies are administered and consumed, driving future growth and innovation within the sector.

Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) continues to make strides in the biotherapeutics space, especially regarding the oral delivery of biologics, as evidenced by its upcoming presentation at ObesityWeek® 2025. The company will present preclinical data demonstrating that its RaniPill® capsule, designed to deliver Semaglutide orally, is bioequivalent to traditional subcutaneous injections, while also eliciting similar weight loss results. This data could be pivotal for Rani, as it aims to replace cumbersome injection methods with a more patient-friendly oral delivery system.

Investors should closely monitor the outcomes of this presentation on November 6, 2025, as positive results could potentially catalyze significant momentum in Rani's stock price. The obesity treatment market remains highly lucrative, and successful demonstration of effective oral delivery could position Rani as a formidable player amid a competitive landscape.

The announcement holds particular weight as obesity continues to be a major public health concern, driving demand for innovative therapies. If Rani's technology indeed mirrors the efficacy of established treatments like Semaglutide injections, it may promote quicker adoption by both patients and healthcare providers, ultimately leading to increased market share.

However, potential investors should be mindful of certain risks. The biotechnology sector often experiences volatility, particularly around clinical data releases. Additionally, regulatory hurdles could delay commercialization efforts. It is crucial to assess Rani’s cash runway and funding strategy, as significant investment is required to advance into clinical trials and potentially bring oral Semaglutide to market.

In conclusion, while the data from ObesityWeek could serve as a catalyst for Rani Therapeutics, careful analysis of the company’s clinical progress and market positioning will be essential for any investment decisions moving forward.